Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EMD 72000+ ECX · 1 trial · 2 indications
| Name | Type | Description |
|---|---|---|
| EMD 72000 (matuzumab) + ECX | DRUG | - |
Inclusion Criteria: * Advanced, recurrent or metastatic gastric adenocarcinoma or adenocarcinoma of the lower third of the esophagus * EGFR positive tumor * KPS greater than 60 * Normal cardiac function * Adequate liver and bone marrow function * GFR greater than 60 ml/minute Exclusion Criteria: ...
Top 20 of 37 competitors
EMD 72000+ ECX is an investigational combination therapy being studied for the treatment of esophageal cancer and gastric cancer. It combines EMD 72000 with the chemotherapy regimen ECX, which includes epirubicin, cisplatin, and capecitabine. The drug is in Phase 1 clinical development for these indications.
EMD 72000+ ECX is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research on this combination therapy for esophageal and gastric cancers.
EMD 72000+ ECX is in Phase 1 clinical development. It is an investigational drug combination and has not been approved by regulatory authorities. The therapy is being studied for safety and tolerability in patients with esophageal and gastric cancers.
EMD 72000+ ECX has one completed clinical trial, NCT00113581, titled "Safety Study of EMD 72000 in Combination With ECX (Epirubicin, Cisplatin and Capecitabine) in Oesophagogastric Cancer." This Phase 1 study enrolled 26 participants in the United Kingdom and included patients aged 18 years and older.
EMD 72000+ ECX is a combination therapy that includes EMD 72000 plus the chemotherapy regimen ECX, which consists of epirubicin, cisplatin, and capecitabine. EMD 72000 alone is a separate investigational agent, while EMD 72000+ ECX refers specifically to the combination being studied.